[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE052828T2 - Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható - Google Patents

Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható

Info

Publication number
HUE052828T2
HUE052828T2 HUE19151824A HUE19151824A HUE052828T2 HU E052828 T2 HUE052828 T2 HU E052828T2 HU E19151824 A HUE19151824 A HU E19151824A HU E19151824 A HUE19151824 A HU E19151824A HU E052828 T2 HUE052828 T2 HU E052828T2
Authority
HU
Hungary
Prior art keywords
triazolopyridine
preparation
synthetic intermediate
intermediate useful
met inhibitors
Prior art date
Application number
HUE19151824A
Other languages
English (en)
Inventor
Hong Jia
Guangxiu Dai
Wei-Guo Su
Original Assignee
Hong Jia
Guangxiu Dai
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE052828(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hong Jia, Guangxiu Dai, Hutchison Medipharma Ltd filed Critical Hong Jia
Publication of HUE052828T2 publication Critical patent/HUE052828T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
HUE19151824A 2009-12-31 2010-12-30 Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható HUE052828T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31

Publications (1)

Publication Number Publication Date
HUE052828T2 true HUE052828T2 (hu) 2021-05-28

Family

ID=44226181

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE20199091A HUE059696T2 (hu) 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk
HUE13198224A HUE025504T2 (hu) 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk
HUE19151824A HUE052828T2 (hu) 2009-12-31 2010-12-30 Szintetikus köztitermék, amely triazolopiridin c-Met gátlók elõállítására használható

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE20199091A HUE059696T2 (hu) 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk
HUE13198224A HUE025504T2 (hu) 2009-12-31 2010-12-30 Triazolopirazin-származékok, készítményeik és alkalmazási eljárásuk

Country Status (38)

Country Link
US (9) US8987269B2 (hu)
EP (5) EP3511330B1 (hu)
JP (5) JP5337313B2 (hu)
KR (3) KR101434766B1 (hu)
CN (3) CN102906092B (hu)
AU (2) AU2010338712B2 (hu)
BR (1) BR112012016129B1 (hu)
CA (1) CA2785749C (hu)
CL (1) CL2012001752A1 (hu)
CO (1) CO6612235A2 (hu)
CU (1) CU24167B1 (hu)
CY (2) CY1118250T1 (hu)
DK (3) DK2719699T3 (hu)
DO (1) DOP2012000188A (hu)
EA (2) EA030141B1 (hu)
EC (1) ECSP12012011A (hu)
ES (4) ES2546635T3 (hu)
GT (1) GT201200220A (hu)
HR (3) HRP20221090T1 (hu)
HU (3) HUE059696T2 (hu)
IL (2) IL220433B (hu)
LT (1) LT3795573T (hu)
ME (1) ME02211B (hu)
MX (2) MX336996B (hu)
MY (1) MY179933A (hu)
NI (1) NI201200118A (hu)
NZ (1) NZ601128A (hu)
PE (3) PE20130375A1 (hu)
PH (1) PH12012501355A1 (hu)
PL (3) PL2719699T3 (hu)
PT (3) PT2719699E (hu)
RS (3) RS61281B1 (hu)
SG (1) SG181781A1 (hu)
SI (2) SI2719699T1 (hu)
SM (3) SMT202200371T1 (hu)
UA (1) UA107822C2 (hu)
WO (1) WO2011079804A1 (hu)
ZA (1) ZA201205730B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2546635T3 (es) 2009-12-31 2015-09-25 Hutchison Medipharma Limited Ciertas triazolopirazinas, composiciones de éstas y sus métodos de empleo
CA2798080C (en) * 2010-05-17 2020-08-25 Incozen Therapeutics Pvt. Ltd. 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
SG11201406185WA (en) * 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
RU2655604C2 (ru) * 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение или его соль
AU2014224382B2 (en) 2013-03-06 2016-11-10 Astrazeneca Ab Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
DK3053923T3 (en) * 2013-09-30 2018-07-23 Korea Res Inst Chemical Tech TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
EA201890061A3 (ru) * 2013-12-26 2018-09-28 Игнита, Инк. Производные пиразоло[1,5-a]пиридина и способы их применения
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
JP6659850B2 (ja) * 2015-12-31 2020-03-04 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド キノリン系化合物の塩、その結晶形、調製方法、組成物及び用途
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3985002B1 (en) 2017-03-01 2025-05-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
JP7629402B2 (ja) * 2018-09-11 2025-02-13 アストラゼネカ・アクチエボラーグ ３－［（１Ｓ）－１－イミダゾ［１，２－ａ］ピリジン－６－イルエチル］－５－（１－メチルピラゾール－４－イル）トリアゾロ［４，５－ｂ］ピラジン及びその多形相の改良製造法
JP2022502500A (ja) 2018-09-25 2022-01-11 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ阻害剤の形態
EP3873905A4 (en) 2018-10-30 2022-08-17 Repare Therapeutics Inc. COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING COMPOUNDS AND THEIR USE AS KINASE ATR INHIBITORS
KR20210111779A (ko) 2018-12-14 2021-09-13 베타 파마, 인크. C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도
CA3123583A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
BR112022000431A2 (pt) * 2019-07-22 2022-03-03 Repare Therapeutics Inc Derivados de 2-morfolinopiridina substituídos como inibidores da atr cinase
WO2021168320A1 (en) * 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
WO2022066534A1 (en) * 2020-09-28 2022-03-31 Codexis, Inc. Engineered biocatalysts and methods for synthesizing chiral amines
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
JP2025513560A (ja) * 2022-04-20 2025-04-24 エングレイル セラピューティクス，インコーポレーテッド Ｇａｂａａ受容体モジュレーター塩、粒子、およびその使用
AU2023303878A1 (en) 2022-07-08 2025-02-27 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
WO2024026410A2 (en) * 2022-07-29 2024-02-01 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
GB202300923D0 (en) * 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
CA2530589A1 (en) * 2003-07-02 2005-01-20 Sugen Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
EP1853602B1 (en) * 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
CA2630884A1 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
EP1966214B9 (en) 2005-12-21 2017-09-13 Janssen Pharmaceutica N.V. Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
JP2009538899A (ja) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
MX2009002842A (es) 2006-09-18 2009-05-27 Vertex Pharma Inhibidores heterociclicos de c-met y usos de los mismos.
ES2393130T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Triazoles bicíclicos como moduladores de proteínas quinasas
US8071581B2 (en) * 2006-10-23 2011-12-06 Sgx Pharmaceuticals, Inc. Triazolopyridazine protein kinase modulators
EP3443958A1 (en) 2006-11-22 2019-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
EA200901157A1 (ru) 2007-04-10 2010-04-30 ЭсДжиИкс ФАРМАСЬЮТИКАЛЗ, ИНК. Конденсированные кольцевые гетероциклические модуляторы киназы
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
ES2376404T3 (es) 2008-05-22 2012-03-13 Amgen Inc. Heterociclos como inhibidores de proteínas cinasas.
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
BR112012003262A8 (pt) * 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
CA2771432A1 (en) * 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
ES2546635T3 (es) * 2009-12-31 2015-09-25 Hutchison Medipharma Limited Ciertas triazolopirazinas, composiciones de éstas y sus métodos de empleo
CA2798080C (en) 2010-05-17 2020-08-25 Incozen Therapeutics Pvt. Ltd. 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

Also Published As

Publication number Publication date
CN106432225B (zh) 2019-02-19
CA2785749C (en) 2017-11-28
US20120245178A1 (en) 2012-09-27
EP2719699A1 (en) 2014-04-16
HK1216880A1 (en) 2016-12-09
PT2719699E (pt) 2015-09-30
ME02211B (me) 2016-02-20
EP3795573A1 (en) 2021-03-24
MX2012007756A (es) 2012-11-06
EA025466B1 (ru) 2016-12-30
EA201691461A1 (ru) 2017-01-30
US20240139182A1 (en) 2024-05-02
IL239997A (en) 2017-11-30
JP2013516393A (ja) 2013-05-13
US20180263977A1 (en) 2018-09-20
IL220433B (en) 2018-01-31
RS61281B1 (sr) 2021-02-26
US10512645B2 (en) 2019-12-24
HUE025504T2 (hu) 2016-02-29
KR101905350B1 (ko) 2018-11-30
SMT201500213B (it) 2015-10-30
EP3795573B1 (en) 2022-07-06
EA030141B1 (ru) 2018-06-29
CN106117248A (zh) 2016-11-16
KR20120125261A (ko) 2012-11-14
CN106432225A (zh) 2017-02-22
EP2519524A4 (en) 2013-07-03
JP6194046B2 (ja) 2017-09-06
PE20160588A1 (es) 2016-07-09
CU24167B1 (es) 2016-03-31
MY179933A (en) 2020-11-19
RS63612B1 (sr) 2022-10-31
HRP20150952T1 (hr) 2015-10-09
CY1118250T1 (el) 2017-06-28
US20200179377A1 (en) 2020-06-11
JP6486999B2 (ja) 2019-03-20
HRP20221090T1 (hr) 2022-11-25
CA2785749A1 (en) 2011-07-07
HRP20202017T1 (hr) 2021-02-19
PH12012501355A1 (en) 2012-12-17
SMT202200371T1 (it) 2022-11-18
CL2012001752A1 (es) 2013-01-25
BR112012016129B1 (pt) 2020-11-03
US11896592B2 (en) 2024-02-13
CO6612235A2 (es) 2013-02-01
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
JP5337313B2 (ja) 2013-11-06
PT3511330T (pt) 2020-12-24
BR112012016129A2 (pt) 2016-05-31
ES2927146T3 (es) 2022-11-02
KR20170098324A (ko) 2017-08-29
RS54217B1 (en) 2015-12-31
SI3511330T1 (sl) 2021-01-29
EP2719699B1 (en) 2015-07-08
US9956218B2 (en) 2018-05-01
EP2966075A1 (en) 2016-01-13
SG181781A1 (en) 2012-07-30
US20170027934A1 (en) 2017-02-02
EP2519524A1 (en) 2012-11-07
CY1123777T1 (el) 2022-03-24
AU2010338712B2 (en) 2015-04-02
EP3511330B1 (en) 2020-09-30
DK2719699T3 (en) 2015-08-24
CN106117248B (zh) 2019-01-22
ECSP12012011A (es) 2012-10-30
KR101771299B1 (ko) 2017-08-24
KR20140059307A (ko) 2014-05-15
LT3795573T (lt) 2022-11-10
US8507487B2 (en) 2013-08-13
UA107822C2 (xx) 2015-02-25
ES2840454T3 (es) 2021-07-06
MX336996B (es) 2016-02-09
SMT202000693T1 (it) 2021-01-05
GT201200220A (es) 2014-12-22
DK3511330T3 (da) 2020-12-21
US20210154192A1 (en) 2021-05-27
US20150368271A1 (en) 2015-12-24
JP6647434B2 (ja) 2020-02-14
ES2546635T3 (es) 2015-09-25
US20250099462A1 (en) 2025-03-27
HK1194071A1 (en) 2014-10-10
PL2719699T3 (pl) 2016-01-29
PL3795573T3 (pl) 2022-11-21
US10946014B2 (en) 2021-03-16
HUE059696T2 (hu) 2022-12-28
JP2016155848A (ja) 2016-09-01
DK3795573T3 (da) 2022-09-19
AU2010338712A1 (en) 2012-07-12
CN102906092A (zh) 2013-01-30
DOP2012000188A (es) 2012-12-31
PL3511330T3 (pl) 2021-04-19
EP3511330A1 (en) 2019-07-17
WO2011079804A1 (en) 2011-07-07
AU2015203480A1 (en) 2015-07-16
PT3795573T (pt) 2022-09-15
EP2966075B1 (en) 2019-02-27
US20120264739A1 (en) 2012-10-18
JP2013209418A (ja) 2013-10-10
CN102906092B (zh) 2016-08-03
JP2019108345A (ja) 2019-07-04
EA201200951A1 (ru) 2013-09-30
US8987269B2 (en) 2015-03-24
KR101434766B1 (ko) 2014-08-26
CU20120101A7 (es) 2012-10-15
SI2719699T1 (sl) 2015-12-31
IL239997A0 (en) 2015-08-31
MX386852B (es) 2025-03-19
ES2726152T3 (es) 2019-10-02
ZA201205730B (en) 2016-01-27
JP2018009004A (ja) 2018-01-18
NZ601128A (en) 2014-12-24
PE20130375A1 (es) 2013-04-10
AU2015203480B2 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
PL3511330T3 (pl) Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met
LT3511330T (lt) Sintetinis tarpinis junginys, naudotinas triazolpiridino c-met inhibitorių paruošimui
IL220091A0 (en) Pcsk9 antagonists
PL2575504T3 (pl) Kompozycja odżywcza wykazująca właściwości immunologiczne
ZA201204266B (en) Antibody formulation
ZA201106503B (en) Antibody formulation
ZA201202906B (en) Novel naphthyridine derivatives and the use thereof as kinase inhibitors
ZA201203242B (en) Antibody formulation
EP2600760A4 (en) IMPROVED LARYNGOSCOPY
ZA201107963B (en) Dentifrice composition
ZA201303811B (en) Triazolopyridine compounds
ZA201004145B (en) Imiquimod formulation
ZA201303661B (en) Cleansing composition
EP2613344A4 (en) POLISHING COMPOSITION
GB0907003D0 (en) Formulation
EP2620160A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
EP2612652A4 (en) DETERGENT COMPOSITION
EP2594255A4 (en) DENTIFRING PASTE COMPOSITION
IL219603A0 (en) Imidazopyridine derivatives
GB0911213D0 (en) Formulation
GB0907410D0 (en) Formulation
GB0910593D0 (en) Carpet rail
GB201005758D0 (en) Buffet train
GB0902472D0 (en) Formulation
GB0906291D0 (en) Formulation